Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Nauck

Showing results (1-10 of 213) with videos related to

Pageof 22
Sort By:
The American Journal of Medicine|January 4, 2011
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implicationsMichael A Nauck
Diabetologia|December 6, 2015
Novel approaches to treating type 2 diabetesMichael A Nauck
Best Practice & Research. Clinical Endocrinology & Metabolism|September 15, 2009
Incretin hormones and their therapeutic potential in patients with type 2 diabetes. PrefaceMichael A Nauck
The American Journal of Medicine|May 26, 2009
Unraveling the science of incretin biologyMichael A Nauck
Metabolism: Clinical and Experimental|December 1, 2019
The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationshipMichael A Nauck
European Journal of Internal Medicine|July 8, 2009
Unraveling the science of incretin biologyMichael A Nauck
Diabetes Care|May 7, 2013
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risksMichael A Nauck
Drug Design, Development and Therapy|September 24, 2014
Update on developments with SGLT2 inhibitors in the management of type 2 diabetesMichael A Nauck
Lancet (London, England)|June 27, 2023
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonistsMichael A Nauck, Michael Horowitz
The Journal of Clinical Endocrinology and Metabolism|May 19, 2025
Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4Michael A Nauck, Waldemar Uhl
Pageof 22

Showing results (1-10 of 213) with videos related to

Sort By:
Pageof 22
The American Journal of Medicine|January 4, 2011
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implicationsMichael A Nauck
Diabetologia|December 6, 2015
Novel approaches to treating type 2 diabetesMichael A Nauck
Best Practice & Research. Clinical Endocrinology & Metabolism|September 15, 2009
Incretin hormones and their therapeutic potential in patients with type 2 diabetes. PrefaceMichael A Nauck
The American Journal of Medicine|May 26, 2009
Unraveling the science of incretin biologyMichael A Nauck
Metabolism: Clinical and Experimental|December 1, 2019
The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationshipMichael A Nauck
European Journal of Internal Medicine|July 8, 2009
Unraveling the science of incretin biologyMichael A Nauck
Diabetes Care|May 7, 2013
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risksMichael A Nauck
Drug Design, Development and Therapy|September 24, 2014
Update on developments with SGLT2 inhibitors in the management of type 2 diabetesMichael A Nauck
Lancet (London, England)|June 27, 2023
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonistsMichael A Nauck, Michael Horowitz
The Journal of Clinical Endocrinology and Metabolism|May 19, 2025
Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4Michael A Nauck, Waldemar Uhl
Pageof 22